The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Background Pertuzumab increases the rate of pathological complete response in the
preoperative context and increases overall survival among patients with metastatic disease …

ABSTRACT The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna,
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …

Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate.
We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be …

Background Clinical trials have shown that trastuzumab, a recombinant monoclonal
antibody against HER2 receptor, significantly improves overall survival and disease-free …